| Name | PF-04979064 |
| Description | PF-04979064 is a potent and selective PI3K and mTOR dual kinase inhibitor, with Ki values of 0.13 nM and 1.42 nM, respectively. |
| In vivo | PF-04979064 was tested against human class I PI3K isoforms α, γ, and δ, with PI3Kα Ki of 0.130 nM, PI3Kγ Ki of 0.111 nM, and PI3Kδ Ki of 0.122 nM.PF-04979064 was progressed to rat in vivo PK studies and exhibited robust PK profile: Vdss = 5.23 L/kg, Cl = 19.3 mL/min/kg, T1/2 = 1.85 h, and F % = 61%. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 4.46 mg/mL (10 mM), Sonication is recommended.
|
| Keywords | Inhibitor | PF-04979064 | Phosphoinositide 3-kinase | Mammalian target of Rapamycin | PF 04979064 | mTOR | PI3K | PF04979064 | inhibit |
| Inhibitors Related | L-Leucine | Capivasertib | Myricetin | Erucic acid | Sapanisertib | (2S,3R,4S)-4-Hydroxyisoleucine | Duvelisib (R enantiomer) hydrochloride | Isoprenaline hydrochloride | Quercetin | Quercetin Dihydrate | Rapamycin | Apilimod |
| Related Compound Libraries | Reprogramming Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Breast Cancer Compound Library | Inhibitor Library | Metabolism Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
United States
